299 related articles for article (PubMed ID: 15590714)
1. In vitro activities of cefotaxime, vancomycin, quinupristin/dalfopristin, linezolid and other antibiotics alone and in combination against Propionibacterium acnes isolates from central nervous system infections.
Mory F; Fougnot S; Rabaud C; Schuhmacher H; Lozniewski A
J Antimicrob Chemother; 2005 Feb; 55(2):265-8. PubMed ID: 15590714
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
3. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
Huang YT; Liao CH; Teng LJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
[TBL] [Abstract][Full Text] [Related]
4. Quinupristin-dalfopristin and linezolid: evidence and opinion.
Eliopoulos GM
Clin Infect Dis; 2003 Feb; 36(4):473-81. PubMed ID: 12567306
[TBL] [Abstract][Full Text] [Related]
5. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.
Raad I; Hachem R; Hanna H; Afif C; Escalante C; Kantarjian H; Rolston K
J Antimicrob Chemother; 2004 Apr; 53(4):646-9. PubMed ID: 14998986
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes.
Tyrrell KL; Citron DM; Warren YA; Fernandez HT; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2006 Aug; 50(8):2728-31. PubMed ID: 16870765
[TBL] [Abstract][Full Text] [Related]
7. European surveillance study on the antibiotic susceptibility of Propionibacterium acnes.
Oprica C; Nord CE;
Clin Microbiol Infect; 2005 Mar; 11(3):204-13. PubMed ID: 15715718
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of quinupristin/dalfopristin and other antibiotics against ampicillin-resistant enterococcus faecium.
Wang FD; Liu IM; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):119-23. PubMed ID: 10677922
[TBL] [Abstract][Full Text] [Related]
9. [Comparative study of treatment with quinupristin-dalfopristin alone or in combination with gentamicin, teicoplanin, imipenem or levofloxacin in experimental endocarditis due to a multidrug-resistant Enterococcus faecium].
Pérez Salmerón J; Martínez García F; Roldán Conesa D; Lorente Salinas I; López Fornás F; Ruiz Gómez J; Gómez Gómez J; Segovia Hernández M; Valdés Chávarri M
Rev Esp Quimioter; 2006 Sep; 19(3):258-66. PubMed ID: 17099794
[TBL] [Abstract][Full Text] [Related]
10. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
Leuthner KD; Cheung CM; Rybak MJ
J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
[TBL] [Abstract][Full Text] [Related]
11. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia.
Erlandson KM; Sun J; Iwen PC; Rupp ME
Clin Infect Dis; 2008 Jan; 46(1):30-6. PubMed ID: 18171210
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus.
Sahuquillo Arce JM; Colombo Gainza E; Gil Brusola A; Ortiz Estévez R; Cantón E; Gobernado M
Rev Esp Quimioter; 2006 Sep; 19(3):252-7. PubMed ID: 17099793
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
14. Treatment of central nervous system infection by vancomycin-resistant enterococcus faecium.
Kanchanapoom T; Koirala J; Goodrich J; Agamah E; Khardori N
Diagn Microbiol Infect Dis; 2003 Mar; 45(3):213-5. PubMed ID: 12663164
[TBL] [Abstract][Full Text] [Related]
15. Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid.
Wareham DW; Abbas H; Karcher AM; Das SS
J Infect; 2006 Apr; 52(4):300-4. PubMed ID: 16099052
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoides and Bacillus thuringiensis to 24 antimicrobials using Sensititre automated microbroth dilution and Etest agar gradient diffusion methods.
Luna VA; King DS; Gulledge J; Cannons AC; Amuso PT; Cattani J
J Antimicrob Chemother; 2007 Sep; 60(3):555-67. PubMed ID: 17586563
[TBL] [Abstract][Full Text] [Related]
17. In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis.
Athamna A; Athamna M; Medlej B; Bast DJ; Rubinstein E
J Antimicrob Chemother; 2004 Apr; 53(4):609-15. PubMed ID: 14998982
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacies of quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus.
Giacometti A; Cirioni O; Ghiselli R; Orlando F; Mocchegiani F; Silvestri C; Licci A; De Fusco M; Provinciali M; Saba V; Scalise G
Antimicrob Agents Chemother; 2005 Oct; 49(10):4042-5. PubMed ID: 16189078
[TBL] [Abstract][Full Text] [Related]
19. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations.
Brauers J; Kresken M; Menke A; Orland A; Weiher H; Morrissey I
Int J Antimicrob Agents; 2007 Mar; 29(3):322-5. PubMed ID: 17204403
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity.
Athamna A; Massalha M; Athamna M; Nura A; Medlej B; Ofek I; Bast D; Rubinstein E
J Antimicrob Chemother; 2004 Feb; 53(2):247-51. PubMed ID: 14688054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
